10 completed, 1 recruiting. 11 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 10, Recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Caliciviridae Infections: new trials by email Literature Review of Caliciviridae Infections trials Research Report on Caliciviridae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate INT101 in Healthy Adults for the Prevention of Norovirus Gastroenteritis INT101 Low Dose, INT101 High Dose, INT101 Placebo (0.25 mL) - Norovirus Infections, Norovirus Gastroenteritis | Phase 1 | Recruiting | InThera Inc. Korea | 30 | 2026-08-10 | 2026-09-14 |
| A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T - Norovirus Infections | Phase 1 | Completed | Vaxart | 60 | 2025-03-03 | 2026-07-27 |
| A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets - Norovirus Infections | Phase 1 | Completed | Vaxart | 76 | 2023-10-27 | 2026-04-15 |
| A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers VXA-G1.1-NN - Norovirus Infections | Phase 1 | Completed | Vaxart | 8 | 2022-01-24 | 2024-06-21 |
| Norovirus Challenge Study VXA-G1.1-NN, Placebo Tablets, Norovirus GI.1 Norwalk Virus Inoculum - Norovirus Infections | Phase 1 / Phase 2 | Completed | Vaxart | 165 | 2021-12-27 | 2025-11-05 |
| Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines VXA-G1.1-NN - Norovirus Infections | Phase 1 / Phase 2 | Completed | Vaxart | 30 | 2021-04-30 | 2024-05-22 |
| Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine VXA-GI.1.NN, Placebo Tablet - Norovirus Infections | Phase 1 | Completed | Vaxart | 66 | 2021-04-26 | 2023-02-13 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）, Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）, Norovirus Bivalent (GI.1 / GII.4) Vaccine（high） - Norwalk Gastroenteritis, Norovirus Infections | Phase 1 | Completed | National Vaccine and Serum Institute, China | 510 | 2019-11-28 | 2021-04-22 |
| Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets - Norovirus Infection | Phase 1 | Completed | Vaxart | 86 | 2019-03-20 | 2022-09-21 |
| Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model Norwalk GI.1 Virus - Norovirus Infection | Phase 1 | Completed | WCCT Global | 16 | 2018-10-03 | 2020-01-22 |
| Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1) Norovirus challenge pool (GII.4, CIN-1) - Norovirus Infections | Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 60 | 2011-08-01 | 2014-05-07 |
Infections (11) · RNA Virus Infections (11) · Virus Diseases (11)
Saline Solution (1)
Vaxart (7) · Children's Hospital Medical Center, Cincinnati (1) · InThera Inc. Korea (1) · National Vaccine and Serum Institute, China (1) · WCCT Global (1)
United States (8) · China (1) · South Africa (1) · South Korea (1)
James Cummings, MD (2) · David Liebowitz, MD, PhD (1) · Helen Paguntalan, MD (1) · Joonsup Yeom, MD, PhD (1) · Mary Beth Manning, MD (1)